Becton, Dickinson and Company $BDX Shares Bought by M. Kulyk & Associates LLC

M. Kulyk & Associates LLC grew its position in Becton, Dickinson and Company (NYSE:BDX) by 8.1% in the third quarter, Holdings Channel.com reports. The fund owned 41,713 shares of the medical instruments supplier’s stock after buying an additional 3,120 shares during the period. Becton, Dickinson and Company makes up approximately 1.6% of M. Kulyk & Associates LLC’s investment portfolio, making the stock its 22nd largest position. M. Kulyk & Associates LLC’s holdings in Becton, Dickinson and Company were worth $7,807,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Becton, Dickinson and Company by 15.4% during the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock valued at $5,565,182,000 after purchasing an additional 4,305,947 shares during the last quarter. Norges Bank acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $653,377,000. First Eagle Investment Management LLC grew its position in shares of Becton, Dickinson and Company by 59.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after buying an additional 3,268,478 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Becton, Dickinson and Company by 24.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after acquiring an additional 1,670,590 shares during the period. Finally, Laurel Wealth Advisors LLC lifted its holdings in Becton, Dickinson and Company by 16,974.4% in the second quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock worth $272,049,000 after acquiring an additional 1,570,136 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.7%

Shares of BDX stock opened at $184.16 on Tuesday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $186.30. The firm has a market capitalization of $52.44 billion, a PE ratio of 30.04, a price-to-earnings-growth ratio of 13.44 and a beta of 0.25. The stock has a fifty day moving average of $197.01 and a two-hundred day moving average of $192.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the business earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has initiated a share repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,416 shares of company stock valued at $675,557 over the last quarter. Insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. TD Cowen upped their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Barclays began coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 target price on the stock. Royal Bank Of Canada set a $172.00 price target on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $195.46.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.